Company intelligence / Profile preview

Decoy Therapeutics

Massachusetts or Texas, USAcreativedestructionlab.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Decoy’s lead candidates have shown promising in silico and in vitro activity against multiple respiratory viruses including RSV and hPIV3. The company is preparing to file an IND for a pan-coronavirus antiviral nasal spray product. No clinical data yet reported.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Peptide-drug conjugates (PDCs)Peptide-conjugate therapeutics
Industry: Biotech

Drug pipeline

3 assets

DCOY101

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

BARDA / Johnson & Johnson Innovation – JLABS BLUE KNIGHT™ collaborationFunding from Bill & Melinda Gates FoundationMassachusetts Life Sciences Seed FundGoogle AI Startup ProgramNVIDIA Inception Program

Beyond the preview

Go deeper on Decoy Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Decoy Therapeutics.

Explore the full profile